Berkeley Heights, NJ, December 3, 2004 -
Genta Incorporated (Nasdaq: GNTA) will host a conference call and
live audio webcast to discuss corporate activities and data
presented during the annual meeting of the American Society of
Hematology (ASH) on Tuesday, December 7, 2004. Genta
management will host the conference call and live audio webcast at
8:30 AM EST.
The conference call can be accessed live as follows:
U.S./Canada: Dial (877) 634-8606, reference Genta
Incorporated.
International: Dial (706) 679-3140, reference Genta
Incorporated.
The webcast will be available in the Investor Relations section of
the Company's website at:
http://www.genta.com/genta/InvestorRelation/events.html
and will be archived for 30 days.
About Genta
Genta Incorporated is a pharmaceutical company with a
diversified product portfolio that is focused on delivering
innovative products for the treatment of patients with cancer. The
Company's research platform is anchored by two major programs that
center on oligonucleotides (RNA and DNA-based medicines) and small
molecules. Genasense
®
(oblimersen sodium) Injection, the Company's lead compound from its
oligonucleotide program is currently undergoing late-stage, Phase 3
clinical testing. The leading drug in Genta's small molecule
program is Ganite
®
(gallium nitrate injection), which the Company is exclusively
marketing in the U.S. for treatment of patients with cancer-related
hypercalcemia that is resistant to hydration. For more
information about Genta, please visit our website at:
http://www.genta.com/
.
This press release and the conference call and webcast to
follow contain forward-looking statements with respect to
business conducted by Genta Incorporated. By their nature,
forward-looking statements and forecasts involve risks and
uncertainties because they relate to events and depend on
circumstances that will occur in the future. There are a number
of factors that could cause actual results and developments to
differ materially. For a discussion of those risks and
uncertainties, please see the Company's Annual
Report/Form 10-K
for 2003.
